作者: Gunter Keller , Diana Steinmann , Alexander Quaas , Viktor Grünwald , Stefan Janssen
DOI: 10.1016/J.ORALONCOLOGY.2017.02.018
关键词:
摘要: Salivary gland carcinomas are rare tumours and therapy strategies less standardized than in lung, gastric or breast cancer. Therapy is based on surgery, but not all completely resectable, e.g. because often show infiltration of nerves. For further decision pathology recommended, evaluation potential targets for personalized part the routine panel. Many salivary can be resistant to radio- and/or chemotherapy, which limits therapeutic options. This review summarizes new concepts carcinoma patients. Targeting growth receptors HER2, EGFR, AR ER possible but, some studies, target molecules were adequately tested before therapy. In addition, approximately 20-25% have RAS mutation (mainly H-RAS), could explain resistance Possible options future immunomodulation (inhibition PDL1/PD1 signalling), nanoparticles (gold conjugated cetuximab increase radiosensitivity) drug delivery systems (trastuzumab emtansine/T-DM1).